Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Long-term Survival Is Linked to Serum LDH and Partly to Tumour LDH-5 in NSCLC

BERNHARD C. DANNER, VASSILIOS N. DIDILIS, STEFAN WIEMEYER, TOMISLAV STOJANOVIC, JULIA KITZ, ALEXANDER EMMERT, LASZLO FÜZESI and FRIEDRICH A. SCHÖNDUBE
Anticancer Research April 2010, 30 (4) 1347-1351;
BERNHARD C. DANNER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bdanner{at}med.uni-goettingen.de
VASSILIOS N. DIDILIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEFAN WIEMEYER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOMISLAV STOJANOVIC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JULIA KITZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALEXANDER EMMERT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LASZLO FÜZESI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FRIEDRICH A. SCHÖNDUBE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Serum LDH values (U l−1) according to tumour LDH level, all patients.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Overall survival curve discriminated for serum LDH levels.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Survival curve for subgroups of patients with a tumour diameter greater than 3 cm and lobectomy discriminated for tumour LDH expression level.

Tables

  • Figures
  • Table I.
  • Table II.
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 30, Issue 4
April 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Long-term Survival Is Linked to Serum LDH and Partly to Tumour LDH-5 in NSCLC
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Long-term Survival Is Linked to Serum LDH and Partly to Tumour LDH-5 in NSCLC
BERNHARD C. DANNER, VASSILIOS N. DIDILIS, STEFAN WIEMEYER, TOMISLAV STOJANOVIC, JULIA KITZ, ALEXANDER EMMERT, LASZLO FÜZESI, FRIEDRICH A. SCHÖNDUBE
Anticancer Research Apr 2010, 30 (4) 1347-1351;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Long-term Survival Is Linked to Serum LDH and Partly to Tumour LDH-5 in NSCLC
BERNHARD C. DANNER, VASSILIOS N. DIDILIS, STEFAN WIEMEYER, TOMISLAV STOJANOVIC, JULIA KITZ, ALEXANDER EMMERT, LASZLO FÜZESI, FRIEDRICH A. SCHÖNDUBE
Anticancer Research Apr 2010, 30 (4) 1347-1351;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Development, internal validation and calibration of a risk score to predict survival in patients with EGFR-mutant non-small cell lung cancer
  • A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung Cancer
  • Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab
  • Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib
  • Google Scholar

More in this TOC Section

  • Pembrolizumab and Quality of Life in Recurrent or Metastatic Head and Neck Cancer
  • Pretreatment Tumor Growth Rate and Clinical Outcomes in Advanced Non–small Cell Lung Cancer
  • Standard Clinical Characteristics Fail to Predict Mild Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients
Show more Clinical Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire